Patents Assigned to EnVivo Pharmaceuticals
-
Patent number: 8367863Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.Type: GrantFiled: June 1, 2012Date of Patent: February 5, 2013Assignee: EnVivo Pharmaceuticals, Inc.Inventors: Gideon Shapiro, Richard Chesworth
-
Patent number: 8343973Abstract: Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.Type: GrantFiled: December 18, 2009Date of Patent: January 1, 2013Assignee: EnVivo Pharmaceuticals, Inc.Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth
-
Publication number: 20120295981Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.Type: ApplicationFiled: June 1, 2012Publication date: November 22, 2012Applicant: EnVivo PHARMACEUTICALS, INC.Inventors: Gideon SHAPIRO, Richard CHESWORTH
-
Patent number: 8217064Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.Type: GrantFiled: December 22, 2008Date of Patent: July 10, 2012Assignee: EnVivo Pharmaceuticals, Inc.Inventors: Gideon Shapiro, Richard Chesworth
-
Patent number: 8071595Abstract: 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.Type: GrantFiled: June 24, 2009Date of Patent: December 6, 2011Assignee: EnVivo Pharmaceuticals, Inc.Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth
-
Publication number: 20110040094Abstract: Compounds that are 1,3,4-trisubstituted benzenes which modulate (e.g., inhibit) the activity of ?-secretase. The compounds are expected to reduce the level of A?42 in patients and be useful in the treatment of diseases (e.g., Alzheimer's disease) characterized by elevated levels of A?42 and/or the formation of A? plaques.Type: ApplicationFiled: September 15, 2008Publication date: February 17, 2011Applicant: ENVIVO PHARMACEUTICALS, INC.Inventors: Gideon Shapiro, Richard Chesworth
-
Publication number: 20100137317Abstract: 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.Type: ApplicationFiled: June 24, 2009Publication date: June 3, 2010Applicant: EnVivo Pharmaceuticals, Inc.Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth
-
Publication number: 20090202108Abstract: A method of system is provided for assaying specimens. In connection with such system or method, plural multi-pixel target images of a field of view are obtained at different corresponding points in time over a given sample period. A background image is obtained using a plural set of the plural target images. For a range of points in time, the background image is removed from the target images to produce corresponding background-removed target images. Analysis is performed using at least a portion of the corresponding background-removed target images to identify visible features of the specimens. A holding structure is provided to hold a set of discrete specimen containers. A positioning mechanism is provided to position a plural subset of the containers to place the moving specimens within the plural subset of the containers within a field of view of the camera.Type: ApplicationFiled: September 15, 2008Publication date: August 13, 2009Applicants: EnVivo Pharmaceuticals, Inc., European Molecular Biology Laboratory, Baylor College of MedicineInventors: Edward Faeldt, Luis Serrano, Cayetano Gonzalez, Christian Boulin, Christopher J. Cummings, Juan Botas, Huda Zoghbi
-
Publication number: 20040255342Abstract: The present invention discloses a transgenic fly that expresses the Iowa mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Iowa peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.Type: ApplicationFiled: May 25, 2004Publication date: December 16, 2004Applicant: EnVivo Pharmaceuticals, Inc.Inventors: David A. Lowe, Gerhard Koenig, Christopher J. Cummings
-
Publication number: 20040255341Abstract: The present invention discloses a transgenic fly that expresses the Arctic mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Arctic peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.Type: ApplicationFiled: May 25, 2004Publication date: December 16, 2004Applicant: EnVivo Pharmaceuticals, Inc.Inventors: David A. Lowe, Gerhard Koenig, Christopher J. Cummings
-
Publication number: 20040250302Abstract: The present invention discloses a transgenic fly that expresses the Dutch mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Dutch peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.Type: ApplicationFiled: May 25, 2004Publication date: December 9, 2004Applicant: EnVivo Pharmaceuticals, Inc.Inventors: David A. Lowe, Gerhard Koenig, Christopher J. Cummings
-
Publication number: 20040244064Abstract: The present invention discloses a transgenic fly that expresses the Flemish mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Flemish peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.Type: ApplicationFiled: May 25, 2004Publication date: December 2, 2004Applicant: EnVivo Pharmaceuticals, Inc.Inventors: David A. Lowe, Gerhard Koenig, Christopher J. Cummings
-
Publication number: 20040126319Abstract: The present invention provides a method for screening for the effect of a test agent on a population of biological specimens, preferably insects, comprising the steps of providing a population of specimens, administering at least one test agent to the population, creating a digitized movie showing the movements of members of the population, measuring at least one trait of members of the population, and correlating the traits of the population with the effect of the test agent. The invention also provides a method for preparing a medicament useful for the treatment of a mammalian disease.Type: ApplicationFiled: October 1, 2003Publication date: July 1, 2004Applicants: Baylor College of Medicine, European Molecular Biology Laboratory (EMBL), EnVivo PharmaceuticalsInventors: Edvard Falt, Luis Serrano, Cayetano Gonzalez, Christian Boulin, Christopher J. Cummings, Juan Botas, Huda Zoghbi
-
Publication number: 20040076999Abstract: Tools are provided for obtaining and assessing data concerning the physical or behavioral traits of an biological specimen population for the purpose of identifying, treating, or gathering intelligence on the condition of the specimen population. In one aspect, a computer system is provided to assess a condition of a biological specimen by studying the physical traits of a sample that comprises a number of specimens. The condition may comprise a human central nervous system condition. A user interface is provided that comprises a computer screen, an input interface portion, and a processing mechanism. The user interface may further comprise a specimen information input mechanism. The specimen information input mechanism may comprise a specimen type input that allows the user to specify, through the computer screen input, the type of specimen to be studied.Type: ApplicationFiled: July 14, 2003Publication date: April 22, 2004Applicants: Baylor College of Medicine, European Molecular Biology Laboratory (EMBL), EnVivo PharmaceuticalsInventors: Edward Faeldt, Luis Serrano, Cayetano Gonzalez, Christian Boulin, Christopher J. Cummings, Juan Botas, Huda Zoghbi
-
Publication number: 20040076318Abstract: A method of system is provided for assaying specimens. In connection with such system or method, plural multi-pixel target images of a field of view are obtained at different corresponding points in time over a given sample period. A background image is obtained using a plural set of the plural target images. For a range of points in time, the background image is removed from the target images to produce corresponding background-removed target images. Analysis is performed using at least a portion of the corresponding background-removed target images to identify visible features of the specimens. A holding structure is provided to hold a set of discrete specimen containers. A positioning mechanism is provided to position a plural subset of the containers to place the moving specimens within the plural subset of the containers within a field of view of the camera.Type: ApplicationFiled: July 14, 2003Publication date: April 22, 2004Applicants: Baylor College of Medicine, European Molecular Biology Laboratory (EMBL), EnVivo PharmaceuticalsInventors: Edward Faeldt, Luis Serrano, Cayetano Gonzalez, Christian Boulin, Christopher J. Cummings, Juan Botas, Huda Zoghbi
-
Publication number: 20040076583Abstract: The present invention provides a method for screening for the effect of a test agent on a population of biological specimens, preferably insects, comprising the steps of providing a population of specimens, administering at least one test agent to the population, creating a digitized movie showing the movements of members of the population, measuring at least one trait of members of the population, and correlating the traits of the population with the effect of the test agent. The invention also provides a method for preparing a medicament useful for the treatment of a mammalian disease.Type: ApplicationFiled: July 14, 2003Publication date: April 22, 2004Applicants: Baylor College of Medicine, European Molecular Biology Laboratory (EMBL), EnVivo PharmaceuticalsInventors: Edward Faeldt, Luis Serrano, Cayetano Gonzalez, Christian Boulin, Christopher J. Cummings, Juan Botas, Huda Zoghbi